India’s pharmaceutical sector, valued at Rs 4,17,345 crore (USD 61.36 billion) in 2023–24, is the world’s third largest by volume and fourteenth by value. The industry supplies 20% of global generic medicines and over 50% of global vaccine demand. In April 2025, it grew 7.8% year-on-year, driven by strong domestic demand and innovation.
With a market capitalization of Rs 27,063.49 crore, the shares of Piramal Pharma Ltd closed at Rs 203.60 per share, increasing around 0.58 percent as compared to the previous closing price of Rs 202.43 apiece.
Piramal Pharma, in its FY25 annual report, unveiled its FY30 vision targeting over 3x EBITDA growth with a 25% margin and more than 2x overall revenue increase.
It aims for $1.2 billion CDMO revenue at 25% margin, $600 million from complex hospital generics with 25%+ margin, and $200 million from consumer health, maintaining double-digit margins.
Looking forward to the company’s financial performance, revenue increased by 8 percent from Rs 2,552 crore in Q4FY24 to Rs 2,754 crore in Q4FY25. Further, during the same time frame, net profit increased by 52 percent from Rs 101 crore to Rs 154 crore.
Piramal Pharma’s CDMO segment posted strong growth with revenues rising 19% in FY24 and 15% in FY25. Innovation-related and differentiated offerings grew significantly, supported by $90 million in capacity expansions.
In Complex Hospital Generics, Piramal maintained leadership in Sevoflurane and Baclofen in the US, while expanding into RoW (Rest of the World) markets with new capacity.
Consumer Healthcare crossed ₹1,000 crore in revenue, driven by power brands, aggressive SKU launches, and digital-first strategies, despite regulatory price cuts on key products like i-pill
For FY26, Piramal Pharma anticipates mid-single-digit consolidated revenue growth and a moderated EBITDA margin in the mid-teens, down from 17% in FY25. This is attributed to reduced ordering from a major on-patent CDMO customer due to inventory normalization. Despite this, PAT is expected to grow modestly, supported by a lower tax rate from improved overseas facility utilization.
Piramal Pharma Limited which offers a portfolio of differentiated pharma products across a domestic and global distribution network. The Company has approximately 17 global facilities and a global distribution network in over 100 countries.
Written by Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Piramal Pharma: The Next Big Bet After $90 Million Expansion & 52% Profit Surge? appeared first on Trade Brains.